SATB2 and colorectal carcinoma: In line with these findings, we additionally observed that SATB2-low/absent CRCs were able to identify patients with a poor prognosis in both CDX2 expression groups (CDX2-low/absent vs. CDX2- high), while CDX2 showed no prognostic relevance in SATB2 expression subgroups, rendering SATB2 as the prognostically superior immunohistochemical biomarker in CRC compared to CDX2.